Market news

IBBQ offers concentrated biotech exposure with lower costs and stronger recent returns, while IYH provides broader sector diversification and higher dividend income.

Invesco's biotech fund surged 56.4% in one year, while Fidelity's broader healthcare portfolio offers lower costs and steadier returns.

VanEck's concentrated 25-stock approach offers higher individual company exposure, while Invesco's broader 251-position portfolio delivered 47.4% returns over the past year.

One offers concentrated exposure to 29 pharma giants with lower volatility, while the other provides broader diversification across 251 biotech companies at a cheaper cost.

RSPH levels the playing field across 60 established healthcare names while IBBQ bets on more than 250 biotech companies at a lower cost.

Vanguard's broad sector approach costs half as much and yields twice the dividend, while Invesco's biotech focus delivered stronger 1-year returns but with steeper downside risk.

One offers global diversification and higher income; the other delivers focused biotech exposure with lower costs and stronger recent gains.

IBBQ surged 54.5% in one year but carries deeper drawdowns. XLV offers broader diversification, lower costs, and double dividend yield for steadier returns.

IBBQ offers lower costs and broader diversification, while XPH delivered stronger 1-year returns with less volatility.